US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Abeona Therapeutics Inc.

< Previous 1 2 3 Next >
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces Date of First Quarter Financial Results
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
News headline image
Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
< Previous 1 2 3 Next >